Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

Agilent collaborates with Seoul National Univ. on new research center

By Drug Discovery Trends Editor | May 13, 2014

Agilent Technologies Inc. this week announced a collaboration with Seoul National Univ., Korea’s top research university, on a new research center that will support the College of Pharmacy’s New Drug Development Center.

As stated in a memorandum of understanding signed by Seoul National Univ.’s College of Pharmacy and Agilent, the collaboration aims to conduct drug metabolism studies; research, evaluate and develop new compounds; understand the remedial effects and toxicity; assess pharmacokinetics; and conduct clinical tests for drugs.

“The College of Pharmacy at Seoul National Univ. has a long tradition of driving innovation,” said professor Bong-Jin Lee, dean of the college. “We have been leading Korea’s pharmaceutical industry through the strategic use of technology and driving the development of new drugs. As we prepare students for the future, we will push the frontiers of drug development by expanding our research facilities, producing outstanding research, and leading the development of technology. We are pleased to collaborate with Agilent, as our scientists and researchers require the latest, most sophisticated instruments for their work.”

Agilent will provide bio-analytical instruments and expertise in pharmaceutical drug testing and multi-omic biological systems to the College of Pharmacy. The jointly established research center will also serve as Agilent’s reference site for drug development.

“One of the megatrends fueling life science research is the aging population,” said Agilent’s Rod Minett, general manager, Life Sciences, South Korea and South Asia-Pacific region. “Through continual research, trials and developments, we believe that newer, more effective drugs can be developed. As such, Agilent is pleased to support SNU College of Pharmacy’s drive to create better drugs for a safer and healthier population.”

This new research facility will be located at the New Drug Development Center at SNU’s College of Pharmacy. The New Drug Development Center is an advanced multi-purpose research center for drug development, from identification of new drugs through to clinical trial testing. The six-story center houses facilities for analysis, efficacy testing, and medicinal ingredient research; it also contains a medicinal chemistry laboratory.

Source: Agilent Technologies

 

Filed Under: Drug Discovery

 

Related Articles Read More >

NIH is reorganizing clinical trial funding by trial type instead of disease
Chemical formula of psilocybin
Psychedelic pioneer Compass files for FDA approval as rivals close in
Insilico’s AI-designed TEAD inhibitor shrank tumors in 4 of 22 mesothelioma patients; randomized Phase 2a planned for 2027
If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE